94 results about "Viral type" patented technology

The invention discloses application of isochlorogenic acid C in preparation of a medicine for resisting a respiratory syncytial virus A type strain, and belongs to the technical field of medicine. Experiments prove that the isochlorogenic acid C has an obvious inhibiting effect on the respiratory syncytial virus type A strain, so that the isochlorogenic acid C has an important application value when being used as an active ingredient for preparing the respiratory syncytial virus type A strain medicine.

The invention provides a capture probe for detecting a human parainfluenza virus whole genome and a kit and application thereof, and relates to the technical field of gene sequencing. The capture probe composition disclosed by the invention comprises probes of which the sequences are shown as SEQ ID NO. 1 to SEQ ID NO. 947. The capture probe composition disclosed by the invention can fully cover the full-length genome of the human parainfluenza virus type 1-4, and has the characteristics of uniformity, specificity and high capture efficiency on a captured region. According to the method, the whole genome sequence of the human parainfluenza virus can be more economically and efficiently obtained through probe hybridization capture and next-generation sequencing technologies, and the purposes of human parainfluenza virus variation monitoring and virus type traceability can be achieved depending on sequence information.

The invention provides a mutant of enterovirus 71 and virus-like particles thereof, and relates to the field of biological medicines. The enterovirus 71 type virus-like particle is obtained by modifying structural genes VP0, VP1 and VP3 of virus capsid protein by utilizing computational structure biology and completing self-assembly in vivo through a hansenula polymorpha expression system. Compared with the unmodified enterovirus 71 type mutant and the virus-like particles thereof, the enterovirus 71 type mutant and the virus-like particles thereof have the advantages that the immunogenicity can be obviously improved, and the clinical application prospect is relatively high.

The invention relates to the technical field of biology. The invention provides a grass carp brain cell line sensitive to grass carp reovirus type II, which is preserved in China Center for Type Culture Collection on October 19, 2024, and the preservation number is CCTCC NO: C2024101. The constructed grass carp brain cell line shows remarkable stability, and stable passage is successfully achieved for 60 times. And when GCRV-II is inoculated, an atypical cytopathic effect can be presented. In addition, the grass carp brain cell line has the capability of efficiently replicating GCRV-II, and even if blind passage is carried out for three generations, generated cytotoxicity can still cause morbidity and death of the grass carp. Therefore, a stable foundation is built for deeply exploring the pathogenic mechanism of the GCRV-II, developing vaccine development, screening antiviral drugs and the like, research in related fields is promoted to further progress, and a key cell model and a research basis are provided for development of related research and prevention and control strategies of the grass carp reovirus.

The invention relates to the technical field of agricultural biology, and particularly provides a dsRNA nanocrystallization preparation for preventing and treating areca yellows as well as a preparation method and application of the dsRNA nanocrystallization preparation. Areca yellows are a destructive disease caused by areca symptomless virus type 1 (APV1), eight key target gene segments of an APV1 virus genome are screened, specific double-stranded RNA is designed, a nano-carrier is used for wrapping and delivering a dsRNA mixture obtained by transcription of the eight target gene segments, and the areca yellows are obtained by screening. And a nanocrystallization preparation for improving the environmental stability and RNA interference efficiency of the dsRNA is prepared. Experimental results show that the nanocrystallization preparation can effectively inhibit the key gene expression of APV1 virus, reduce the virus load and improve the resistance of areca catechu to yellows. The invention provides an accurate, efficient and environment-friendly biological prevention and control strategy, and has a wide agricultural application prospect.

The invention provides a probe library for high-throughput detection of mouse and hamster related species-specific viruses in a CHO cell library and application of the probe library. The probe library is used for detecting a mouse pox virus, a hantavirus, a K virus, a lactic dehydrogenase virus, a lymphocytic choriomeningitis virus, a mouse microvirus, a mouse adenovirus, a mouse cytomegalovirus, a mouse encephalomyelitis virus, a mouse hepatitis virus, a mouse rotavirus, a mouse pneumovirus, a multiple oma virus, a reovirus type 3 and a sendai virus; sV5 and thymoviruses and variant viruses thereof. The high-throughput sequencing method based on the probe library can be used for distinguishing viral nucleic acid with infection risk and quickly checking whether a sample is polluted by specific live viruses or not. The detection limit reaches the level of a traditional PCR method, the capability of detecting all known variants of to-be-detected species-specific viruses is kept, 17 viruses can be detected only by implementing one detection item, and the method has the advantages of high efficiency, rapidness and high sensitivity.

The invention discloses a formula of kyllinga breviscapus for preventing and treating EV71 type infection, and relates to the technical field of medicines, and the formula comprises the following steps: S1, taking kyllinga breviscapus, and adding 6 times of volume of water into the kyllinga breviscapus; s2, decocting for three times, and decocting for 1 hour each time; s3, filtering the decoction, and merging the filtrate; and S4, carrying out reduced pressure concentration at-80 DEG C (the vacuum degree is-0.090 to-0.1 MPa) to obtain freeze-dried powder. Compared with the prior art, the application has the advantages that the enterovirus 71 is a microRNA viridae enterovirus group A member EV71, the kyllinga breviscapus has good inhibitory activity on the enterovirus 71, and the kyllinga breviscapus has important clinical application value on treatment of diseases infected with the enterovirus 71.

The invention relates to a nucleic acid detection platform based on an SHERLOCK technology, which is used for diagnosing CAV-2. The SHERLOCK consisting of recombinase polymerase nucleic acid pre-amplification (RPA) and CRISPR-Cas13a is mainly used for specifically recognizing a conserved sequence of CAV-2RNA (Ribonucleic Acid) through crRNA (Complementary Ribonucleic Acid) so as to activate the non-specific'side cutting activity 'of lwCas13a, so that the report RNA is degraded. A real-time fluorescent quantitative PCR (qPCR) system or a lateral flow test strip is used for collecting fluorescent signals generated by cracking of the reporter molecules, and a visual result is displayed. In addition, through HUDSON treatment, RPA-CRISPR can be amplified at room temperature without viral nucleic acid extraction. The detection limit of the method is 1.1 * 10 < 2 > copies / [mu] L, and the method has no cross reaction with other canine infectious viruses. From sample collection to result output, the whole reaction of RPA-CRISPR can be completed within two hours, and the RPA-CRISPR kit is suitable for rapid test of clinical samples and can work well in the field or in primary laboratories. The method can get rid of the limitation of a detection instrument and complex operation, and is suitable for on-site rapid batch detection. The method is preliminarily verified and further optimized and applied.

The invention relates to the technical field of avian virus detection, and particularly discloses a primer probe combination, a kit and a method for simultaneously detecting chicken infectious anemia virus and chicken circle virus type 3 based on fluorescent RAA and application. The method can be used for simultaneously detecting the chicken infectious anemia virus and the chicken circle virus type 3, and has the advantages of simplicity in operation, short detection time, good specificity, high sensitivity, no need of expensive instruments and equipment, support of on-site rapid detection, suitability for large-scale popularization and application and the like; and effective technical support can be provided for rapid detection and screening of the chicken infectious anemia virus and the chicken circle virus type 3.

A chimpanzee adenovirus vector from newly discovered and isolated chimpanzee adenovirus with unique HVR sequences and a method of its construction and application thereof, with higher viral titer, and provides a method for determining its viral titer. The chimpanzee adenovirus circular vector is constructed through a shuttle plasmid, and knocks out E1 and E3 to construct a replication-defective chimpanzee adenovirus vector. The chimpanzee adenovirus vector described in this article has no preexisting antibody in the population, and the knockout of E1 and E3 is safe. At the same time, it is significantly different from human adenovirus type 5 E1 in 293 cells, which can greatly avoid recovery mutation (RCA) and make it safer. The novel coronavirus vaccine has strong stability and does not cause mutations after multiple passages, and it can induce strong humoral immunity and cellular response in mouse models.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The invention relates to the field of biological medicine, and provides a coxsackie virus A16 type mutant and a virus-like particle thereof, compared with a wild type coxsackie virus A16 type, the mutant has at least one amino acid mutation site in the following regions: (1) a canyon region of a virus capsid; (2) a channel area at a secondary axis; or (3) a channel region at a quasi-tertiary axis. The mutant and the virus-like particle are obtained by optimizing and modifying structural proteins VP0, VP1 and VP3 which form a virus capsid by using computational biology and structural biology methods, co-expressing and co-assembling the structural proteins in a hansenula polymorpha expression system to form the virus-like particle, and then carrying out series of chromatographic purification. Compared with a non-mutated coxsackie virus A16 type virus-like particle mutation scheme, the coxsackie virus A16 type virus-like particle mutation scheme disclosed by the invention has the advantages that the antigen immunogenicity can be obviously improved, and the clinical application value is realized.

The present invention relates to the field of biotechnology. The present invention provides a grass carp brain cell line sensitive to grass carp reovirus type II, which was deposited in the China Center for Type Culture Collection on October 19, 2024, with a deposit number of CCTCC NO: C2024101. The grass carp brain cell line constructed by the present invention shows remarkable stability and successfully achieved 60 stable passages. When inoculated with GCRV‑II, an atypical cytopathic effect can be exhibited. In addition, the grass carp brain cell line has the ability to efficiently replicate GCRV‑II, and even after three generations of blind transmission, the generated cytotoxin can still cause grass carp to become ill and die. Therefore, the present invention has laid a solid foundation for in-depth exploration of the pathogenic mechanism of GCRV‑II, vaccine development, and antiviral drug screening, which will help promote further progress in related research and provide a key cell model and research basis for the formulation of grass carp reovirus-related research and prevention and control strategies.

The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.

The invention relates to key antigen epitope screening, in particular to an echovirus 18 type key antigen epitope peptide and application thereof. The result of an enzyme-linked immunosorbent assay shows that Epitope 1 (SEQ ID NO: 1) can be effectively combined with E18-VP1 antiserum, and the combining capacity is obviously higher than that of Epitope 2 in a blank control and a negative result, so that one antigen epitope peptide is screened based on the complete sequence of the echovirus 18-VP1, and the antigen epitope peptide has important guiding significance for research and development of echovirus 18 vaccines.

The invention discloses an application of alpha-lipoic acid in preparation of an anti-iridovirus drug. Related experiments show that alpha-lipoic acid can safely and effectively treat iridovirus such as frog virus type 3, not only can effectively reduce harm of iridovirus to frog and fish culture, but also can promote ecological high-quality development of aquaculture industry, and has obvious economic and social benefits.

The invention belongs to the field of biology, and discloses a broad-spectrum neutralizing porcine monoclonal antibody for foot-and-mouth disease virus type O and its application. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The key amino acid residue of the antigen recognized by the monoclonal antibody is position 77 of the VP2 protein. The site is located in the VP2B-C loop of the structural protein and is a conformational epitope. The site does not react with type A antigen, is a broad-spectrum neutralizing antibody within the type, and exhibits a strong neutralizing efficacy (IC 50 <5μg·mL ‑1 ). At the same time, the present invention also provides the application of the monoclonal antibody.

The present application discloses a method for preventing and treating flue-cured tobacco virus disease, belonging to the field of plant protection. The method comprises (1) prevention: applying agents during the seedling stage, before transplanting, after transplanting, and during the field stage of tobacco growth; during the seedling stage: applying guanidine-copper acetate before thinning, replanting, and weeding; applying amino oligosaccharides and antiviral microbial agents before sealing the trays; applying cinclostrobin acetate solution after sealing the trays and before cutting the leaves; applying ningnanmycin and amino oligosaccharides before and after transplanting; applying insecticides mixed with plant resistance inducers, antiviral microbial agents, trace elements, and foliar fertilizers from one week after transplanting the seedlings to the stage of clustering; (2) treatment of the disease. The method prevents flue-cured tobacco virus disease by applying antiviral agents early in the whole growth stage of tobacco; and combining the antiviral agents with other specific agents to improve tobacco plant resistance, reduce the incidence of viral diseases, and improve the cure rate of viral diseases.

Described herein are systems and methods that may be used to differentially detect viral serotype specific nucleic acid. For example, these systems may comprise multiple DNA-nanostructures, capture oligonucleotides and protector oligonucleotides, wherein each DNA-nanostructure and its associated capture oligonucleotide and protector oligonucleotide are specific for a unique viral type or serotype.

The application provides a fusion protein, a rabbit hemorrhagic disease virus type 2 self-assembled nanoparticle vaccine and application, and belongs to the technical field of biological medicine. The application provides a fusion protein, which comprises a first polypeptide, a hinge region of a rabbit hemorrhagic disease virus type 2 capsid protein, a P region of a rabbit hemorrhagic disease virus capsid protein and a second polypeptide connected in sequence; the first polypeptide and the second polypeptide are polypeptides containing four cysteines respectively. The fusion protein RGD4C-HP-RGD4C of the application can self-assemble to form nanoparticles, and the particle size is 40-50 nm. The fusion protein of the application can induce domestic rabbits to produce specific antibodies against RHDV2, produce a strong humoral immune response, and provide complete protection for the domestic rabbits.

The invention discloses an RT-PSR (Reverse Transcription-Polymerase Chain Reaction) detection kit for coxsackie virus A6 in the technical field of PSR rapid detection kits. The RT-PSR detection kit for coxsackie virus A6 is high in sensitivity, and the detection limit of the coxsackie virus A6 is as low as 1 * 10 < 1 > copies / mu L; the detection time is short, the detection result can be obtained within 60 minutes, while the common fluorescent quantitative PCR takes 120 minutes; the method has low requirements on instruments and equipment, does not need complex detection instruments such as a PCR instrument and a sensor, and judges whether amplification occurs only through color change of an indicator; compared with an immunological technology, the cost is lower, and the sensitivity is higher; the operation is simple, the process does not need to operate complex instruments, and the reaction can be completed only through water bath or metal bath.

The invention discloses a grass carp reovirus type II mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof, and belongs to the field of vaccines. According to the technical scheme, the grass carp reovirus type II mRNA vaccine comprises a modified mRNA chain, the modified mRNA chain sequence comprises a 5 'UTR sequence, a Kozak sequence, a grass carp immunoglobulin mu heavy chain signal peptide coding sequence, a GCRV II outer capsid protein VP35 coding sequence, three termination codons, a 3' UTR sequence and a polyA nucleotide sequence. The GCRV II mRNA vaccine is applied to enhancing the GCRV infection resistance of a fish body, the death rate is reduced, and the blank of the current grass carp reovirus II mRNA vaccine is filled.

The present invention provides an aminonitrothiazole derivative for use in the preparation of a drug for preventing and treating viral infections and related diseases caused thereto, and belongs to the field of pharmaceuticals. The structure of the aminonitrothiazole derivative is shown in Formula I. Experimental results show that the compound can effectively inhibit the activity of respiratory syncytial virus, enterovirus 71, and the new coronavirus, and the inhibitory effect is better than that of the positive controls nitazoxanide and lauric acid. The compound provided by the present invention can be used to prepare a drug for preventing and / or treating viral infections, and can be used to prepare a drug for preventing and / or treating related diseases caused by viruses, and has broad application prospects.

The invention belongs to the technical field of veterinary biology, and particularly relates to a swine foot and mouth disease virus O-type immune peptide fusion protein as well as a preparation method and application thereof. The invention provides a swine foot and mouth disease virus O-type immune peptide fusion protein. The swine foot and mouth disease virus O-type immune peptide fusion protein has an amino acid sequence as shown in SEQ ID NO: 1. The technical problems that in the prior art, antigen peptides adopted in FMDV-O immunization are insufficient in immunity and insufficient in protective efficacy are solved.

The invention belongs to the technical field of veterinary biology, and particularly relates to a swine foot and mouth disease virus type A immune peptide fusion protein as well as a preparation method and application thereof. The invention provides a swine foot-and-mouth disease virus type A immune peptide fusion protein. The swine foot-and-mouth disease virus type A immune peptide fusion protein has an amino acid sequence as shown in SEQ ID NO: 1. Compared with an epitope predicted in the prior art, the recombinant immune composite peptide provided by the invention has better immunogenicity, can obtain a neutralizing antibody with higher titer, and has better animal protection capacity.

The invention provides a fusion protein, a rabbit hemorrhagic disease virus type 2 self-assembled nanoparticle vaccine and application, and belongs to the technical field of biological medicine. The invention provides a fusion protein. The fusion protein comprises a first polypeptide, a hinge region of a rabbit hemorrhagic disease virus type 2 capsid protein, a P region of the rabbit hemorrhagic disease virus capsid protein and a second polypeptide which are connected in sequence, the first polypeptide and the second polypeptide are respectively polypeptide containing four cysteines. The fusion protein RGD4C-HP-RGD4C disclosed by the invention can be self-assembled to form nano particles, and the particle size is 40 to 50 nm. The fusion protein provided by the invention can induce a rabbit to generate a specific antibody aiming at RHDV2, generate a relatively strong humoral immune response and provide complete protection for the rabbit.

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The present disclosure relates to the field of biological medicine, and provides a mutant of coxsackievirus A16 and a virus-like particle thereof, wherein the mutant has at least one amino acid mutation site in the following regions compared with wild-type coxsackievirus A16: (1) a canyon region of a virus capsid; (2) a channel region at a dihedral axis; or (3) a channel region at a quasi-trihedral axis. The mutant and the virus-like particle are obtained by optimizing and modifying structural proteins VP0, VP1 and VP3 constituting the virus capsid by using computational biology and structural biology methods, co-expressing and co-assembling the structural proteins into the virus-like particle in vivo in a Hansenula yeast expression system, and then purifying the virus-like particle by serial chromatography. The mutation scheme of the coxsackievirus A16 virus-like particle in the present disclosure can significantly improve the antigen immunogenicity compared with the unmutated virus-like particle, and has clinical application value.

The invention relates to the technical field of viral vaccines, and particularly discloses a purification method of coxsackie virus 16. The invention discloses a method for purifying coxsackie virus 16, which comprises the following steps in sequence: pre-treating a virus ultrafiltration concentrated solution, and then carrying out ion exchange gel chromatography to obtain a virus purified solution; the pretreatment comprises the following specific steps: adding Triton-X100, trimethyl citrate and histidine into a virus ultrafiltration concentrated solution, and incubating for 2-4 hours at 10-18 DEG C; then adding glycerol, and incubating for 20-60 minutes at the temperature of 20-30 DEG C; the ion exchange gel chromatography adopts a flow-through process, and a Capto Q Impres gel medium is used for carrying out ion exchange gel chromatography. By means of the technical scheme, the separation efficiency of the coxsackie virus type 16 target product can be effectively improved, and the recovery rate of the coxsackie virus type 16 purified liquid product and the removal rate of impurity protein are guaranteed.